Polychemotherapy for early breast cancer: Results from the international adjuvant breast cancer chemotherapy randomized trial

Journal of the National Cancer Institute

Volumn 99, Issue 7, 2007, Pages 506-515

  Bliss, Judith M ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; TAMOXIFEN; ANTINEOPLASTIC AGENT; CMF REGIMEN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; EARLY CANCER; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; OVARIECTOMY; OVERALL SURVIVAL; POLYPHARMACY; PREMENOPAUSE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RISK ASSESSMENT; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT RESPONSE; UNITED KINGDOM; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CANCER STAGING; DRUG COMBINATION; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; POSTMENOPAUSE; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; QUESTIONNAIRE; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG THERAPY, COMBINATION; FEMALE; FLUOROURACIL; HUMANS; METHOTREXATE; MIDDLE AGED; NEOPLASM STAGING; POSTMENOPAUSE; QUALITY OF LIFE; QUESTIONNAIRES; RECEPTORS, ESTROGEN; RESEARCH DESIGN; SURVIVAL ANALYSIS;

EID: 34247603457     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djk108     Document Type: Article

References (37)

1. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. 133 randomized trials involving 31000 recurrences and 24000 deaths 75000 women. Lancet 1992;339:1-15, 71-85.
2. Clemons M, Danson S, Howell A. Tamoxifen ('Nolvadex'): A review. Cancer Treat Rev 2002;28:165-80.
3. Early Breast Cancer Trialists' Collaborative Group. Treatment of early breast cancer. Vol 1.: Worldwide evidence 1985-1990. Oxford: Oxford University Press; 1990.
4. Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976;294:405-10.
5. Kerr DJ, Earl HM, Baker PG, Jevons CM, Lee MJ, Baum M, et al. aTTom - adjuvant tamoxifen treatment, offer more? Br J Cancer 1996; 74(Suppl):528.
6. Peto R. Five years of tamoxifen - or more? [editorial]. J Natl Cancer Inst 1996;88:1791-3.
7. Jasani B, Douglas-Jones A, Rhodes A, Wozniak S, Barrett-Lee P, Gee J, et al. Measurement of estrogen receptor status by immunocytochemistry in paraffin wax sections. Methods Mol Med 2006;120:127-46.
8. Barnes DM, Harris WH, Smith P, Millis RR, Rubens RD. Immunohistochemical determination of estrogen receptor: Comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Cancer 1996;74:1445-51.
9. Fisher B, Brown AM, Dimitrov NV, Poisson R, Redmond C, Margolese RG, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen nonresponsive tumours: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990;8: 1483-96.
10. Pritchard KI, Paterson AH, Paul NA, Zee B, Fine S, Pater J. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol 1996;14:2731-7.
11. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. QLQ-C30: A quality-of-life instrument for use in International Clinical Trials in Oncology. J Natl Cancer Inst 1993;85:365-76.
12. Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: First results from a three-country field study. J Clin Oncol 1996;14: 2756-68.
13. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-70.
14. Thirlaway K, Fallowfield L, Cuzick J. The sexual activity questionnaire: a measure of women's sexual functioning. Qual Life Res 1996;5:81-90.
15. Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: Results from a United Kingdom national questionnaire survey. Br Med J 1998;316:736-41.
16. Fayers PM, Aaronson NK, Bjordal K, Curran D, Groenvold M. EORTC Quality of Life Study Group. EORTC QLQ-C30 scoring manual. 3rd ed. Brussels (Belgium): EORTC Quality of Life Group; 2001. p. 86.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-81.
18. StataCorp. Stata statistical software: Release 8.0. College Station (TX): Stata Corporation; 2003.
19. Liang K-Y, Zegler SL. Longitudinal data analysis using generalised linear models. Biometrika 1986;73:13-22.
20. Clark TG, Altman DG, De Stavola BL. Quantification of the completeness of follow-up. Lancet 2002;359:1309-10.
21. Early Breast Cancer Trialists' Collaborative Croup. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomized trials. Lancet 2005;365: 1687-717.
22. Poole CJ, Earl HM, Hiller L, Dunn JA, Bathers S, Grieve RJ, et al. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med 2006;355: 1920-2.
23. Henderson C, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976-83.
24. Martin M, Rodriguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, et al. Multicenter, randomized phase III study of adjuvant chemotherapy for node-positive breast cancer comparing 6 cycles of FEC versus 4 cycles of FEC followed by 8 weekly paclitaxel administrations: Interim analysis of GEICAM 9906 trial. Breast Cancer Res Treat 2005; 94(Suppl 1):S20.
25. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C. TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients, BCIRG 001: 55 months follow-up. Breast Cancer Res Treat 2003;82(Suppl 1).
26. Roche H, Fumoleau P, Spielman M, Canon JL, Delozier T, Kerbrat P, et al. Five years analysis of the PAC01 trial: 6 cycles of FEC 100 versus 3 cycles of FEC 100 followed by 3 cycles of docetaxel for the adjuvant treatment of node positive breast cancer. Breast Cancer Res Treat 2004;88 (Suppl 1):A27.
27. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer: Results of North American Breast Cancer Intergroup Trial E1199. San Antonio Breast Cancer Symposium 2005 (December 8-11); Abstract 038.
28. Prozato P, Cazzaniga ME, Mustacchi G, Di Costanzo F, de Matteis A, Pareu L, et al. Applications of new adjuvant treatments for node positive (N+) breast cancer (BC) patients (pts) in Italian centres. Results of the NORA (National Oncological Research Observatory on Adjuvant Therapy in Breast Cancer) Study. Proc Am Soc Clin Oncol 2005; 24:aBstract 878).
29. Colleoni M, Coates A, Pagani O, Goldhirsch A. Combined chemoendocrine adjuvant therapy for patients with operable breast cancer: Still a question?. Cancer Treat Rev 1998;24:15-26.
30. Goldhirsch A, Colleoni M, Coates AS, Castiglione-Gertsch M, Gelber RD. Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: are all CMFs alike? The International Breast Cancer Study Group (IBCSG). Ann Oncol 1998;9:489-93.
31. Pribylova O, Petruzelka LB, Shumansky K, Spinelli JJ, Ragaz J. Randomized trial of adjuvant equitoxic dose-escalated anthracycline (A)-containing regimen of doxorubicin, cyclophosphamide (AC) versus cyclophosphamide, methotrexate, 5FU (CMF) for stage I-II breast cancer (BrCa): Can equitoxicity compensate for agent selection. Proc Am Soc Clin Oncol 2005;24:aBstract 818.
32. Albain K, Barlow W, O'Malley F, Siziopikou K, Yeh I-T, Ravdin P, et al. The Breast Cancer Intergroup of North America. Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen and/or progesterone receptor-positive breast cancer: Mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG-8814). San Antonio Breast Cancer Symposium 2004 (December 8-11).
33. Castiglione-Gertsch M. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: A randomized trial. The International Breast Cancer Study Group (IBCSG). J Natl Cancer Inst 2003;95:1833-46.
34. Pagani O, O'Neill A. Castiglione M, Gelber RD, Goldhirsch A, Rudenstam C, et al. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer 1998;34:632-640.
35. Jordan VC. Chemotherapy is antihormonal therapy - how much proof do oncologists need? Eur J Cancer 1998;34:606-8.
36. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996;14:2738-46.
37. Barrett-Lee P, Ellis P, Bliss J. TACT Trial Management Group. Duration of adjuvant chemotherapy; andiracyclines, taxanes and novel agents-more or less. Clin Oncol (R Coll Radiol) 2002;14:263-6.